It takes a village: Do we need to rethink our attitude to old age? April 10, 2025 We’re living for longer than ever but the boom in the elderly population is a social and political time-bomb. Could ‘later life’ communities like Auriens be the answer to the old age crisis, asks Steve Dinneen I enter a grand lobby, all lofty ceilings, marquetry floors and art deco fittings. An effusive concierge in a natty [...]
Bionow Awards honour our greatest Innovators April 9, 2025 | Sponsored The Bionow Awards are given to honour those most deserving for their ingenuity and dedication, distinguishing them from their competitors and proving them worthy of recognition. With a prestigious history of more than 20 years, the awards have become the leading life sciences accolades in the UK; highlighting the achievements of the sector, shining a [...]
Hikma’s profit jumps as demand for generic medicines booms February 26, 2025 Hikma Pharmaceuticals reported a strong financial performance for 2024, with revenue rising nine per cent to $3.13bn (£2.47bn) and operating profit up 67 per cent to $612m (£483m). Profit attributable to shareholders nearly doubled, reaching $359m (£284m), while earnings per share rose 88 per cent. The multinational pharmaceutical company that develops, manufactures, and markets a [...]
FTSE 100 giant GSK eyes more than £40bn in sales by 2031 February 5, 2025 Pharmaceutical giant GSK has hiked its 2031 sales forecast to more than £40bn, up from £38bn, after reporting better than forecast fourth quarter earnings. The London-listed pharma giant reported core earnings per share of 23.2p for the quarter, a drop of around 20 per cent year-on-year. However, this was greater than the 19p that analysts [...]
Astrazeneca boosts cardiovascular pipeline with licensing deal October 7, 2024 Astrazeneca has struck a licensing agreement worth up to $2bn (£1.5bn) with China’s CPSC Pharmaceutical Group to develop a new cardiovascular drug, the company announced on Monday. The Anglo-Swedish pharmaceutical giant will pay $100m (£76.5) upfront, with additional milestone payments of up to $1.9bn (£1.4bn), to licence a preclinical small molecule aimed at treating dyslipidemia. [...]
